Avalon’s ACE Strategy
Avalon is committed to its strategic plan, ACE, which is pivotal in achieving the Company’s ambitious goal of becoming a 1 billion pharmaceutical leader by 2030. Developed in 2024, the strategy is cantered on three pillars: Accelerate, Catalyse, and Expand.
This strategic decision (ACE strategy) will position Avalon as a leading player in multiple pharmaceutical segments. Responsible for executing the new strategy, and to ensure its success, the Company’s latest division, the Strategy Management Office (SMO), which is due to officially launch in 2025, will spearhead the implementation of all initiatives
Business Model & Operational Review
The following sections delve into the key pillars of Avalon’s business model:
Products
Showcasing a broad portfolio spanning critical therapeutic areas and consumer-focused solutions.
Manufacturing
Highlighting world-class facilities, sustainability initiatives, and a relentless focus on quality.
Business Development
Exploring strategies for partnerships, licensing, and market expansion to drive long-term growth.
Avalon Pharma’s business model is built on a robust framework that integrates innovation, operational excellence, and strategic growth. By combining a diverse product portfolio, state-of-the-art manufacturing capabilities, and dynamic business development strategies, the Company ensures sustainable success while meeting the evolving needs of its stakeholders.
The model reflects Avalon’s commitment to quality, agility, and customer-centric solutions. Each element is meticulously aligned with its mission to develop and deliver high-quality healthcare products and its vision of being a leader in the health, beauty, and wellness sectors. Through continuous investment in research, technology, and strategic alliances, Avalon remains at the forefront of the pharmaceutical and healthcare industries.